InstalabLoading...
InstalabLoading...
Your kidneys can lose more than half their function before you feel anything wrong. One of the most dangerous causes of silent kidney damage is a condition where your own immune system attacks the tiny blood vessels in your kidneys, lungs, and other organs. MPO Antibody (myeloperoxidase antibody, also called MPO-ANCA) is the test that catches this attack. If it comes back positive, you have a specific type of autoantibody circulating in your blood that is strongly linked to a group of diseases called ANCA-associated vasculitis, or AAV, which means inflammation of blood vessels driven by these particular antibodies.
This is not a routine screening test. It is a targeted diagnostic tool with high specificity, meaning a positive result in the right clinical context carries real weight. Understanding what this result means, when it can mislead, and how to track it over time can make the difference between catching organ damage early and discovering it after permanent harm has been done.
Myeloperoxidase is a powerful enzyme stored inside neutrophils, the most common type of white blood cell. Normally, when neutrophils arrive at an infection site, they release MPO to generate bleach-like chemicals that kill bacteria. The enzyme itself is not the problem. The problem begins when your immune system mistakenly produces antibodies against MPO.
These anti-MPO autoantibodies bind to MPO on the surface of activated neutrophils. This triggers the neutrophils to release their toxic contents directly into the walls of small blood vessels, causing inflammation, tissue death, and scarring. The test measures the level of these autoantibodies in your blood. It does not measure how much MPO enzyme you have. That distinction matters because studies about circulating MPO enzyme levels (used in some cardiovascular research) are measuring a completely different thing than this test.
The kidneys are the organ most frequently and seriously damaged by MPO-ANCA-associated vasculitis. The autoantibodies drive a specific pattern of kidney injury in which tiny blood-filtering units called glomeruli are destroyed by inflammation and scarring, without the typical immune deposits seen in other forms of kidney disease.
In a population-based study of 201 patients with ANCA-associated kidney inflammation, those with MPO-ANCA had a worse chance of keeping their kidneys working long-term compared to those with the other main ANCA type, called PR3-ANCA (proteinase 3 antibody). MPO-ANCA kidney disease was more likely to progress to end-stage kidney disease requiring dialysis, even after accounting for how much kidney function remained at diagnosis.
A separate study of 126 patients with kidney-predominant ANCA vasculitis found that when MPO-ANCA levels rose during remission, the risk of relapse climbed sharply. The adjusted risk of relapse was roughly 17 times higher in patients whose ANCA levels increased compared to those whose levels stayed stable, with a median gap of just 0.6 months between the rise in antibody level and the clinical flare. That is a remarkably short window, which is why serial monitoring matters so much in this disease.
MPO-ANCA is not only a vasculitis marker. It also shows up in people with unexplained scarring lung disease. Among 305 patients diagnosed with idiopathic interstitial pneumonia (a group of lung-scarring conditions with no clear cause), about 8.5% tested positive for MPO-ANCA. Over five years, roughly 24% of those MPO-ANCA-positive patients went on to develop microscopic polyangiitis, a form of small-vessel vasculitis. None of the MPO-ANCA-negative patients developed it.
A separate study of 58 patients with interstitial lung disease and positive anti-MPO antibodies found that many later developed systemic autoimmune disease, most commonly AAV. These findings suggest that if you have unexplained lung scarring and a positive MPO-ANCA, you should be monitored closely for signs of vasculitis, even if you feel well otherwise.
ANCA-associated vasculitis comes in two main immunologic flavors, defined by which antibody you carry: MPO-ANCA or PR3-ANCA (proteinase 3 antibody). These are not interchangeable. A study of 315 patients from a German vasculitis center found that MPO-ANCA-positive patients with granulomatosis with polyangiitis (GPA, formerly called Wegener's) had a distinct clinical course and lower relapse rates compared to PR3-ANCA-positive GPA patients. Patterns of immune signaling molecules in the blood also differ significantly between MPO and PR3 disease.
This is why modern classification of AAV increasingly relies on ANCA type (MPO vs. PR3) rather than the traditional disease labels alone. The antibody you carry tells your doctor more about your likely course, relapse risk, and treatment response than the clinical category by itself.
MPO-ANCA is a high-specificity test. In a meta-analysis of ANCA testing for vasculitis, anti-MPO blood tests had a pooled specificity of about 96%, meaning that fewer than 4 in 100 people without vasculitis would get a false positive. Sensitivity (the test's ability to detect vasculitis when it is actually present) is more variable: about 58% overall for all AAV, but much higher for microscopic polyangiitis specifically (around 73%) and lower for GPA (around 11%), since most GPA patients carry PR3-ANCA instead.
When MPO-ANCA and PR3-ANCA tests are used together, the combined system catches about 86% of systemic vasculitis cases with 99% specificity. A large European Vasculitis Study Group evaluation of 1,175 samples found that modern tests designed to detect specific antibodies directly (antigen-specific immunoassays for anti-MPO and anti-PR3) outperform the older screening method, called indirect immunofluorescence, which looks for a staining pattern under a microscope rather than measuring specific antibodies. The newer tests achieved diagnostic accuracy scores of 0.94 to 0.96 on a 0-to-1 scale, compared to 0.84 to 0.92 for the older method.
A negative MPO-ANCA result does not rule out vasculitis. Some patients with biopsy-proven AAV are ANCA-negative. If your doctor suspects vasculitis based on your symptoms and other lab work, a negative MPO-ANCA should prompt additional investigation, not reassurance.
MPO-ANCA results are typically reported as either positive or negative, sometimes with a numeric titer (a number reflecting how much antibody is in your blood) in units that vary by lab method (AI, U/mL, or EU). There are no universally standardized "optimal" or "normal" ranges the way there are for cholesterol or blood sugar. Different labs use different testing platforms, and numeric cutpoints are not directly comparable across labs.
What matters most is the magnitude of positivity and the clinical context. A multicentre evaluation showed that looking at how strongly positive the result is, rather than just whether it is positive or negative, substantially improves interpretation: a strongly positive result carries far more diagnostic weight than a weakly positive one. Higher titers have a much higher chance of reflecting true AAV, while low-positive results are more ambiguous and require careful clinical correlation.
If your result includes a numeric value, compare it only within the same lab and testing method over time. A rising titer at the same lab is far more meaningful than comparing absolute numbers between two different labs.
Several situations can produce a positive MPO-ANCA without true ANCA-associated vasculitis, or cause you to misinterpret a result:
For anyone with established MPO-ANCA-associated vasculitis, serial monitoring is not optional. It is one of the most valuable tools for catching relapse early. A study of 271 patients in remission found that reappearance of MPO-ANCA (after it had become negative during treatment) was strongly associated with subsequent relapse. Another study found that rising titers during remission preceded clinical flares by a median of just 0.6 months.
If you are being treated for AAV, your rheumatologist or nephrologist will typically check MPO-ANCA levels every three to six months during the first two years, then at least every six to twelve months during maintenance. If you are on immunosuppressive therapy and your titer starts climbing, that is a signal to reassess, even if you feel fine.
For someone who tested positive incidentally (for example, during a workup for unexplained kidney or lung problems), a single positive result should be confirmed with a repeat test, ideally using the same testing method, along with companion tests and clinical evaluation before any major decisions are made.
One of the most striking findings in the MPO-ANCA literature is that these antibodies can appear years before symptoms begin. A case-control study using stored blood samples from a population biobank found that MPO-ANCA was present a median of about 2 years before the first symptoms of AAV, and in some individuals up to 10 years before diagnosis. People who later developed AAV with kidney, lung, or nerve involvement were more likely to have had positive MPO-ANCA in their pre-symptomatic blood samples.
This does not mean that screening healthy people for MPO-ANCA is warranted. There is no evidence that finding MPO-ANCA in an asymptomatic person and acting on it improves outcomes. But it does mean that if you have a positive result and any concerning symptoms, even subtle ones like unexplained blood in your urine, new breathing difficulty, or numbness in your hands or feet, the antibody may have been building for longer than you realize.
If your MPO-ANCA is negative and you have no symptoms of vasculitis, this result is reassuring in that specific context. You do not need routine repeat testing unless new symptoms develop.
If your MPO-ANCA is positive, the next steps depend on whether you have symptoms. A positive result with kidney involvement (blood or protein in the urine, rising creatinine), lung symptoms, skin lesions, or nerve problems should prompt urgent evaluation by a rheumatologist or nephrologist. Companion tests to order include a urinalysis with microscopy, serum creatinine with eGFR (estimated glomerular filtration rate, a measure of kidney function), PR3-ANCA, CRP (C-reactive protein, a general inflammation marker), and a complete blood count. A kidney biopsy may be needed to confirm the diagnosis and guide treatment intensity.
If your MPO-ANCA is positive but you have no symptoms, confirm the result with a repeat test. Check kidney function, urinalysis, and inflammatory markers. If everything else is normal, monitoring every six months is reasonable, with instructions to seek evaluation promptly if new symptoms appear. A positive MPO-ANCA in someone with existing interstitial lung disease should prompt formal vasculitis surveillance, given the roughly 24% five-year risk of developing microscopic polyangiitis in that population.
Evidence-backed interventions that affect your MPO Antibody level
Myeloperoxidase Antibody is best interpreted alongside these tests.